TESARO (TSRO) Announces Collaboration with China's Zai Lab
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
TESARO, Inc. (NASDAQ: TSRO) and Zai Lab (Shanghai) Co., Ltd., a biopharmaceutical company based in China, announced a collaboration to support the development and commercialization of niraparib for patients in China and the potential to advance two immuno-oncology programs outside of China. This partnership reflects the commitment of both companies to develop novel therapeutic approaches for people living with cancer around the world.
Within this collaboration, TESARO has granted to Zai Lab an exclusive license for the development of niraparib specifically for the China market, which includes an option for TESARO to participate in the commercialization of niraparib in greater China. The companies will establish a joint steering committee to review and oversee all development and commercialization plans. In addition, TESARO has the option to license two novel, discovery-stage immuno-oncology programs from Zai Lab.
“TESARO is devoted to providing transformative therapies for people bravely facing cancer, and this partnership will enable us to globalize our mission,” said Lonnie Moulder, CEO of TESARO. “The Zai Lab team has a track record of regulatory and development successes in China, and we are excited to work with them to quickly advance new treatment options for patients.” Samantha Du, Chairman and CEO of Zai Lab, added, “We are delighted to partner with TESARO, a leader in global oncology drug development. Ovarian and other cancer types that niraparib is being evaluated in are areas of large unmet medical need in China, with very limited treatment options. Our collaboration with TESARO will bring this exciting new product candidate quickly to the Chinese patients, and we look forward to working with TESARO.”
In addition to an upfront payment, TESARO will be eligible to receive milestone payments contingent upon Zai Lab achieving certain specified development and commercial goals. Should TESARO elect not to participate in the commercialization of niraparib in China, TESARO will be eligible to receive tiered, double-digit royalty payments on annual net sales from Zai Lab. Additional financial details were not disclosed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TESARO (TSRO) Niraparib EAP Opens in U.S. for Ovarian Cancer
- FDA Approves Generic of Xyrem With REMS Program; Jazz Pharmaceuticals (JAZZ) Shares Decline
- Apricus Biosciences (APRI) Vitaros Approved in Mexico for Erectile Dysfunction
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!